Navigation Links
Kiadis Pharma Announces Promising Phase II Clinical Trial Results for Reviroc
Date:8/30/2007

GRONINGEN, Netherlands, Aug. 31 /PRNewswire-FirstCall/ -- Oncology focused pharmaceutical development company Kiadis Pharma announced today that it has successfully completed a Phase II clinical trial evaluating its product Reviroc(TM). Reviroc is used to eliminate cancer cells from an autologous graft in bone marrow transplantations for end-stage blood cancer patients. Data from the clinical study revealed improved overall survival of Reviroc-treated patients. The successful completion of the clinical trial allows Kiadis Pharma to prepare for a Phase III clinical study.

Manja Bouman, CEO, Kiadis Pharma, comments: "We are obviously very pleased with the completion of this Phase II trial of Reviroc. It brings treatment with our product a step closer to patients with end stage blood cancer. Reviroc shares its development platform with two other Kiadis Pharma products: ATIR and Rhitol. The results of this trial therefore mark an important milestone in the development of our entire clinical product pipeline."

In the non-randomized open label study 25 patients, each of whom had reached end stage Non-Hodgkin's lymphoma, were treated in multiple centers in Canada. The objective of the study was to determine the safety of the Reviroc treatment and its ability to eliminate cancer cells from a contaminated graft. Reviroc-treated grafts all showed excellent engraftment, indicating that Reviroc does not negatively impact the graft itself.

The Reviroc clinical trial data was evaluated against a historical patient control group from the Center for International Blood and Marrow Transplant Research (CIBMTR). The results for Reviroc-treated patients were compared with results from the CIBMTR database for patients who had received an autologous transplant without Reviroc. The outcome of this comparison shows that the Reviroc-treated patient group had an 80% chance of survival at 3 years post transplantation, while the CIBMTR control group had a 55% chance of survival at 3 years post transplantation. Based on these promising data, Kiadis Pharma will prepare for a clinical phase III study of Reviroc.

Dr. Denis-Claude Roy at Maisonneuve-Rosemont Hospital in Montreal, commented: "After more then five years of clinical research, we believe that our results demonstrate that Reviroc is able to improve patient survival. This is potentially a breakthrough achievement for patients suffering from Non-Hodgkin's lymphoma as well as their families."

About Reviroc

Reviroc is being developed as a treatment that eliminates blood cancer cells from autologous transplants for patients with end stage blood cancer. An autologous transplant uses the patient's own bone marrow to serve as a graft. Bone marrow transplantations are broadly recognized as a treatment option for patients suffering from blood cancers, such as leukemia and lymphoma. Reviroc has been developed to remove residual tumor cells from the graft.

About Kiadis Pharma

Kiadis Pharma is an oncology focused pharmaceutical development company with four products in different phases of clinical development. The company develops products that offer novel treatment options for terminally ill cancer patients and address high unmet medical needs. Key areas for Kiadis Pharma are clinical indications in blood cancers and solid tumors. Kiadis Pharma is headquartered in the Netherlands with facilities in Groningen, the Netherlands and Montreal, Canada. For more information about Kiadis Pharma, please visit http://www.kiadis.com


'/>"/>
SOURCE Kiadis Pharma
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Sygnis Pharma AG announces date for presentation of clinical results
2. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
3. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
7. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
8. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
9. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
10. Array BioPharma to Present at the C.E Unterbeg, Towbin Emerging Growth Conference
11. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... -- Research and Markets has announced ... Applications, Technologies, Forecasts" report to their offering. ... Smart Skin, Structural Health Monitoring, Composite Smart Structures, ... involves electronic and/or electrical components and circuits that ... such as vehicle bodies or conformally placed upon ...
(Date:6/24/2016)... June 24, 2016 Research and Markets ... for Companion Diagnostic Tests" report to their offering. ... Companion Diagnostics The World Market for Companion ... medicine diagnostics. Market analysis in the report includes the following: ... (In Vitro Diagnostic Kits) by Region (N. America, EU, ROW), ...
(Date:6/24/2016)... 2016  Arkis BioSciences, a leading innovator in ... durable cerebrospinal fluid treatments, today announced it has ... is led by Innova Memphis, followed by Angel ... investors.  Arkis, new financing will accelerate the commercialization ... release of its in-licensed Endexo® technology. ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... June 27, 2016 , ... "FCPX editors can now ... of Final Cut Pro X," said Christina Austin - CEO of Pixel Film Studios. ... Final Cut Pro X users can now reveal the media of their split ...
(Date:6/26/2016)... ... 27, 2016 , ... Quality metrics are proliferating in cancer care, and are ... the eye of the beholder, according to experts who offered insights and commentary in ... Managed Care. For the full issue, click here . , For the American ...
(Date:6/26/2016)... Michigan (PRWEB) , ... June 26, 2016 , ... ... to fertility once they have been diagnosed with endometriosis. These women need a ... they also require a comprehensive approach that can help for preservation of fertility ...
(Date:6/25/2016)... ... ... First Choice Emergency Room , the largest network of independent freestanding emergency ... its new Mesquite-Samuell Farm facility. , “We are pleased to announce Dr. Ogunleye ... M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. , Dr. Ogunleye ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published June ... with. The article goes on to state that individuals are now more comfortable seeking ... common operations such as calf and cheek reduction. The Los Angeles area medical group, ...
Breaking Medicine News(10 mins):